Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders.

ABSTRACT:

Background

Aripiprazole (ARI) is the first-line treatment for tic disorders (TD). Cytochrome P450(CYP)2D6 (CYP2D6) and ATP-binding cassette, sub-family B, member 1 (ABCB1) transporter are involved in the metabolism of ARI. However, whether CYP2D6 and ABCB1 genetic polymorphisms influence clinical efficacy and pharmacokinetics of ARI remains unclear.

Methods

CYP2D6 and ABCB1 genotyping were performed. Pharmacokinetic parameters of ARI and its metabolite dehydroaripiprazole (DARI) were derived using a previously established population pharmacokinetic model. Drug response after ARI administration was evaluated based on reduction rate of Yale Global Tic Severity Scale score (YGTSS).

Results

Steady-state DARI/ARI metabolic ratios (MRs) of AUC_0 - t, C_min

SUBMITTER: Xin Y 

PROVIDER: S-EPMC12220787 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature